A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 125 participants.
Also called NCT07239570
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 125 participants
- Sponsor
- Registry
-
NCT07239570
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark, Germany, Spain, Sweden
- Registry status
- Recruiting
Technical summary
Registry record NCT07239570. Randomized; no masking; primary purpose treatment. Start 2025-06-20 (actual); primary completion 2028-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
- Acronym
- CKD-bioMatch
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Finerenone
- Lead sponsor
- Peter Rossing
- Collaborator
- University Medical Center Groningen
- Collaborator
- Lund University
- Collaborator
- Instituto de Investigacion Sanitaria INCLIVA
- Collaborator
- Universitätsklinikum Hamburg-Eppendorf
Record details
- Record id
cardio:ct-nct07239570- Content hash
91119ecec080389a86e7859d1f8eb3693d9266b54c8df84a6e04c8843f42d28a